Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umberto Capitanio

Showing results (11-20 of 516) with videos related to

Pageof 52
Sort By:
European Urology Focus|July 21, 2017
Repeat Prostate Biopsy: Rationale, Indications, and StrategiesUmberto Capitanio, David Pfister, Mark Emberton
European Urology|June 30, 2026
Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024Antonio Cigliola, Andrea Necchi, Umberto Capitanio
European Urology|February 4, 2019
Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661-7 and 2019;75:198Alessandro Antonelli, Andrea Minervini, Umberto Capitanio
The Journal of Urology|February 26, 2021
Editorial CommentGiuseppe Fallara, Alessandro Larcher, Umberto Capitanio
BJU International|January 19, 2019
Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomyUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
European Urology|July 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?Umberto Capitanio, Francesco Montorsi, Alessandro Larcher
Annals of Translational Medicine|February 5, 2020
Acute kidney injury after partial nephrectomy: transient or permanent kidney damage?-Impact on long-term renal functionGiuseppe Rosiello, Umberto Capitanio, Alessandro Larcher
European Urology Focus|October 1, 2019
Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002Francesco Montorsi, Alessandro Larcher, Umberto Capitanio
European Urology|November 7, 2021
Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683-94: Adjuvant Pembrolizumab After Nephrectomy: A Plea to Reconsider the Need for Lymph Node DissectionUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
The Journal of Urology|March 1, 2019
Editorial CommentAlessandro Antonelli, Andrea Minervini, Umberto Capitanio
Pageof 52

Showing results (11-20 of 516) with videos related to

Sort By:
Pageof 52
European Urology Focus|July 21, 2017
Repeat Prostate Biopsy: Rationale, Indications, and StrategiesUmberto Capitanio, David Pfister, Mark Emberton
European Urology|June 30, 2026
Re: Alexander D. Sherry, Van To, Criselle D'souza, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.03.024Antonio Cigliola, Andrea Necchi, Umberto Capitanio
European Urology|February 4, 2019
Reply to Steven C. Campbell, Chalairat Suk-Ouichai, and Yun-Lin Ye's Words of Wisdom re: Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Antonelli A, Minervini A, Sandri M, et al. Eur Urol 2018;74:661-7 and 2019;75:198Alessandro Antonelli, Andrea Minervini, Umberto Capitanio
The Journal of Urology|February 26, 2021
Editorial CommentGiuseppe Fallara, Alessandro Larcher, Umberto Capitanio
BJU International|January 19, 2019
Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomyUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
European Urology|July 23, 2019
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For?Umberto Capitanio, Francesco Montorsi, Alessandro Larcher
Annals of Translational Medicine|February 5, 2020
Acute kidney injury after partial nephrectomy: transient or permanent kidney damage?-Impact on long-term renal functionGiuseppe Rosiello, Umberto Capitanio, Alessandro Larcher
European Urology Focus|October 1, 2019
Re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2019.06.002Francesco Montorsi, Alessandro Larcher, Umberto Capitanio
European Urology|November 7, 2021
Re: Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 2021;385:683-94: Adjuvant Pembrolizumab After Nephrectomy: A Plea to Reconsider the Need for Lymph Node DissectionUmberto Capitanio, Alessandro Larcher, Francesco Montorsi
The Journal of Urology|March 1, 2019
Editorial CommentAlessandro Antonelli, Andrea Minervini, Umberto Capitanio
Pageof 52